

NIMV CAP SEVERA

Anna Maria Brambilla

*Pronto Soccorso e Medicina d'Urgenza
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milano*

ricovero?



dove?

terapia

sepsi grave

insufficienza respiratoria acuta

Table 4. Criteria for severe community-acquired pneumonia.

Minor criteria^a

Respiratory rate^b ≥ 30 breaths/min

PaO₂/FiO₂ ratio^b ≤ 250

Multilobar infiltrates

Confusion/disorientation

Uremia (BUN level, ≥ 20 mg/dL)

Leukopenia^c (WBC count, < 4000 cells/mm³)

Thrombocytopenia (platelet count, $< 100,000$ cells/mm³)

Hypothermia (core temperature, $< 36^\circ\text{C}$)

Hypotension requiring aggressive fluid resuscitation

Major criteria

Invasive mechanical ventilation

Septic shock with the need for vasopressors

Table 4. Criteria for severe community-acquired pneumonia.

Minor criteria^a

Respiratory rate^b ≥ 30 breaths/min

PaO₂/FiO₂ ratio^b ≤ 250

Multilobar infiltrates

Confusion/disorientation

Uremia (BUN level, ≥ 20 mg/dL)

Leukopenia^c (WBC count, < 4000 cells/mm³)

Thrombocytopenia (platelet count, $< 100,000$ cells/mm³)

Hypothermia (core temperature, $< 36^\circ\text{C}$)

Hypotension requiring aggressive fluid resuscitation

Major criteria

Invasive mechanical ventilation

Septic shock with the need for vasopressors

36% arf


20% arf + ss

RESEARCH

Open Access

Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis

Stefano Alliberti¹, Anna Maria Brambilla², James D Chalmers³, Catia Cilloniz⁴, Julio Ramirez⁵, Angelo Bignamini⁶, Elena Prina², Eva Polverino⁴, Paolo Tarsia⁷, Alberto Pesci¹, Antoni Torres⁴, Francesco Blasi^{7*} and Roberto Cosentini²



	Group A (Neither ARF nor SS)	Group B (Only ARF)	Group C (Both ARF and SS)
All patients, n.	954 (45)	771 (36)	420 (20)
Patients who died, n.	43	72	108
Patients who died, % (95%CI)*	4.2 (3.3-6.1)	9.3 (7.4-11.7)	26 (22-30)

* p<0.001 among three groups

Figure 1 In-hospital mortality of the study population according to the three study groups. Group A: Community-acquired pneumonia (CAP) patients with neither acute respiratory failure (ARF) nor severe sepsis (SS) on admission. Group B: CAP patients with only ARF on admission. Group C: CAP patients with both ARF and SS on admission. n: number.





Figure 3 Multivariable logistic model with respect to in-hospital mortality. ARF: acute respiratory failure; SS: severe sepsis; COPD: chronic obstructive pulmonary disease; ABT: antibiotic empiric therapy; ERS: European Respiratory Society; OR: odds ratio; CI: confident intervals. All the variables are present vs. absent, but age (1-year change), male (vs. female) and multilobar (vs. monolobar).


IPOSSIA



ipoperfusione tissutale

infiammazione

ossigeno ponte all'efficacia antibiotico-terapia



REVIEW

Cardiac diseases complicating community-acquired pneumonia

Stefano Alberti¹ and Julio A. Ramirez²



CHEST



Original Research

CHEST INFECTIONS


Early Cardiac Arrest in Patients Hospitalized With Pneumonia

danni cardiovascolari

effetto shunt



O₂ terapia



shunt non migliora

PRESSIONE POSITIVA



NIV e POLMONITE

guidelines
ipossiemia
immunodepresso

DNI
trapiantato
polipatologico
anziano
immunocompetente
primo tentativo nell'ARF
pandemie virali

10% dell'uso della NIV per
de novo ARF in europa



osservazionali



ipossiémico

Antonelli 2001
Wang 2013 (retro, arf)
Thille 2013

immunodepresso

Gregg 1990
Conti 1998
Hilbert 2000
Azoulay 2001
Confalonieri 2002
Rabitsch 2005

polmonite

Nicolini, 2012 HINI
Stefan 2013 ARF
Jolliet 2001
Carron 2010
Nicolini 2014
Carrillo 2012
Masclans 2013
DOmenighetti 2002

RCT

ipossiémico

Ferrer 2003
DelClauX 2000 (tutti)
Antonelli 2000

immunodepresso

Gachot 1992
Hilbert 2001
Principi 2004
Squadrone 2010
Antonelli 2000

polmonite

Confalonieri 1999
Cosentini 2010
Brambilla 2014

osservazionali



ipossiémico

Antonelli 2001
Wang 2013 (retro, arf)
Thille 2013

immunodepresso

Gregg 1990
Conti 1998
Hilbert 2000
Azoulay 2001
Confalonieri 2002
Rabitsch 2005

polmonite

Nicolini, 2012 HINI
Stefan 2013 ARF
Jolliet 2001
Carron 2010
Nicolini 2014
Carrillo 2012
Masclans 2013
DOmenighetti 2002

RCT

ipossiémico

Ferrer 2003
DelClaux 2000 (tutti)
Antonelli 2000

immunodepresso

Gachot 1992
Hilbert 2001
Principi 2004
Squadrone 2010
Antonelli 2000

polmonite

Confalonieri 1999
Cosentini 2010
Brambilla 2014



OXYGEN THERAPY FOR PNEUMONIA IN ADULTS (REVIEW)

Cochrane Database Syst Rev. 2012 Mar

Confalonieri 1999

RCT, multicentre

CAP grave

Inclusi: acidosi respiratoria acuta

56 pazienti (41% BPCO) – ICU

NPPV maschera
vs venturi mask



Hillbert 2001

RCT

Immunodepressi con
- infiltrati polmonari
- febbre
- P/F < 200 in venturi

Esclusi: acidosi respiratoria acuta,
causa cardiaca

52 pazienti – ICU

NPPV maschera
vs venturi mask



Cosentini 2010


RCT, multicentrico

CAP
con ipossiemia
moderata

Esclusi: acidosi respiratoria
acuta, causa cardiaca

57 pazienti – ED


CPAP con helmet
vs maschera venturi





OXYGEN THERAPY FOR PNEUMONIA IN ADULTS (REVIEW)

Cochrane Database Syst Rev. 2012 Mar





Conclusioni

Authors' conclusions

Non-invasive ventilation can reduce the risk of death in the ICU, endotracheal intubation, shorten ICU stay and length of intubation. Some outcomes and complications of non-invasive ventilation were varied according to different participant populations. Other than the oxygen therapy, we must mention the importance of standard treatment by physicians. The evidence is weak and we did not include participants with pulmonary tuberculosis and cystic fibrosis. More RCTs are required to answer these clinical questions. However, the review indicates that non-invasive ventilation may be more beneficial than standard oxygen supplementation via a Venturi mask for pneumonia.

non-invasive ventilation may be more beneficial than standard oxygen supplementation

The evidence is weak

More RCTs are required to answer these clinical questions.

**Anna Maria Brambilla
Stefano Aliberti
Elena Prina
Francesco Nicoli
Manuela Del Forno
Stefano Nava
Giovanni Ferrari
Francesco Corradi
Paolo Pelosi
Angelo Bignamini
Paolo Tarsia
Roberto Cosentini**

Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia

inclusion criteria

pneumonia
distress, RR > 30, PF < 250



Table 2 Primary endpoint

	CPAP group (n = 40)	Control group (n = 41)	p
Met ETI criteria, n (%)	6 (15.0)	26 (63.4)	<0.001
Major criteria			
Hemodynamic instability	0	1	0.320
Intolerance to device	2	0	0.463
Minor criteria			
PO ₂ /FiO ₂ ratio dropped by ≥30 % from baseline	3	13	0.014
Worsening of alertness	0	3	0.248
New onset or persistent respiratory distress	4	24	<0.001
SpO ₂ <90 %	1	11	0.006
Exhaustion	0	4	0.130

CPAP continuous positive airway pressure, n number, ETI endotracheal intubation, SpO₂ oxygen saturation. Twenty-four patients met two criteria, three patients met one criteria, and five patients met three criteria of ETI. Other major criteria such as respiratory

arrest and respiratory pauses with unconsciousness, and other minor criteria such as increasing of 20 % of PaCO₂ if basal PaCO₂ was 40 mmHg or higher were met in neither study group

number needed to treat: 2 (CI95% 1-3)

entro le 12 ore
peggioramento




Fig. 2 Kaplan–Meier analysis of time to the primary endpoint. *CPAP* continuous positive airway pressure, *ETI* endotracheal intubation

RESULTS: Between February 2010 and 2013, 40 patients were randomized to CPAP and 41 to Venturi mask. The proportion of patients meeting ETI criteria in the CPAP group was significantly lower compared to those in the control group ($6/40 = 15\%$ vs. $26/41 = 63\%$, respectively, $p < 0.001$; relative risk 0.24, 95% CI 0.11-0.51; number needed to treat, 2) two patients were intubated in the CPAP group and one in the control group. The CPAP group showed a faster and greater improvement in oxygenation in comparison to controls ($p < 0.001$). In either study group, no relevant adverse events were detected.

Conclusions

Helmet CPAP reduces the risk of meeting ETI criteria compared to oxygen therapy in patients with severe hARF due to pneumonia.

Andres Carrillo
Gumersindo Gonzalez-Diaz
Miquel Ferrer
Maria Elena Martinez-Quintana
Antonia Lopez-Martinez
Noemi Llamas
Maravillas Alcazar
Antoni Torres

Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure

studio prospettico 184 pts in ICU
successo NIV 64%

Fallimento NIV

46% in de novo ARF
vs
30% in precedente malattia
cardio/respiratoria
(p 0.007)

Fattori rischio mortalità

dopo 1 ora di NIV: alta FC, basso pO_2/FiO_2 ,
fallimento NIV
SOFA
età

STUDIO PROSPETTICO OSSERVAZIONALE
MULTICENTRICO “REAL LIFE” SULL’USO DELLA
CPAP/NIV NEL TRATTAMENTO DELLA
POLMONITE

studio “3P”
Pneumonia
Positive
Pressure



nel 2013, **20** Centri Italiani, **342** polmoniti trattate con CPAP/NIV

	CPAP (171)	NIV (171)
Efficacia	106 (62%)	108 (63%)
Interruzione x intolleranza	10 (6%)	12 (7%)
Passaggio a NIV	33 (19%)	/
IOT	11 (6.4%)	22 (12.9%)
mortalità	43 (25%)	40 (23.4%)

**Fattori prognostici
di mortalità**

età
polmonite bilaterale
anemia
azotemia alta
PSI alto

DNI
neoplasia
sepsi grave

protettivi
obesità
BPCOr

1.



2.

1 o 2 pressioni?



3.




monitoraggio

4.

don't delay ETI
if necessary





grazie per
l'attenzione